India, Aug. 11 -- Shattuck Labs Inc. (STTK), a clinical-stage biotechnology company, on Tuesday announced financial results for the second quarter, noting a higher loss due to increased operating expenses.
The company is focused on developing monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases.
Q2 Financial Results:
Net loss in the second quarter came to $15.15 million or $0.12 per share, higher than the $12.46 million or $0.24 per share from a year ago.
Loss from operations were $16.15 million this year, the same was recorded as $13.03 million in the second quarter of 2025.
The company recorded Research and Development (R&D) expenses at $11.70 million, consider...